hCG During TRT — When Is It Used, and Does It Help Preserve Fertility?

A man qualifying for testosterone replacement therapy sooner or later hears from his doctor (or stumbles onto online) a suggestion to add human chorionic gonadotropin, or hCG for short, to the protocol. For some patients, this is their first encounter with the abbreviation at all; for others, it's a topic they've read about in fragments on forums and groups, without clarity on whether it's something they should actually consider or just another "just in case" protocol add-on generating extra cost and extra injections.

This article doesn't explain hCG's mechanism from the ground up — we do that in detail in a separate knowledge-base post on hCG as adjunct therapy to TRT, which we link to below throughout. Here we focus on the practical question: what this dosing actually looks like in real clinics, what to realistically expect in terms of preserving fertility, how much it costs, and — most importantly — who hCG is a sensible choice for, and who needs something else because it isn't enough.

Testosterone given from outside the body as part of TRT suppresses the pituitary's secretion of LH (luteinizing hormone) — the brain "sees" a high blood testosterone level and curtails its own signal to the testes, regardless of where that testosterone came from. Without LH, the Leydig cells in the testes stop being stimulated to produce testosterone locally, and it's precisely that local, intratesticular testosterone concentration — not the blood concentration — that's crucial for proper spermatogenesis. hCG's structure is similar enough to LH that it binds the same receptors on Leydig cells and can stimulate them regardless of what's happening at the pituitary level. In other words: hCG "tricks" the testis into continuing to work as if it were still receiving an LH signal, even though the natural signal has been switched off by the testosterone therapy itself.

This is a place worth being honest about: hCG dosing for fertility preservation during TRT isn't a single, standardized protocol handed down by endocrine societies — it's an area where different doctors and different andrology clinics use different schedules, based on available clinical data, their own experience, and each patient's individual response. There's no single "correct" dose to give as a universal answer — there are a few recurring patterns.

In practice, injections are given subcutaneously (less often intramuscularly) — hCG in powder form is reconstituted right before use, or shortly before, and stored in the fridge after reconstitution. For many men it's one additional, thin-needle subcutaneous injection into the abdomen — technically very similar to what some patients already know from testosterone injections, not requiring a separate, more complicated procedure.

The most frequently cited study on hCG and preserving fertility during TRT is a retrospective analysis from a team at Baylor College of Medicine, published in the Journal of Urology in 2013. It's worth knowing its real numbers, since they give a good sense of the scale of the effect — and its limits.

This is encouraging data, but it needs to be read at the right scale: it's a retrospective study on a small, selected group of 26 men, without a control group treated with testosterone alone observed in parallel within the same study, and without full, standardized semen analyses (spermiograms) for all participants at baseline and during treatment — part of the conclusion about preserved fertility rests on the fact that a pregnancy occurred, not on a detailed analysis of sperm count and quality for each individual patient. This is a strong clinical signal, but not proof at the level of a large, randomized trial with a hard endpoint for every participant.

Additional, earlier physiological data — from the Coviello et al. (2005) study, covered in more depth in our post on hCG in TRT — show the mechanism behind this effect: low doses of hCG added to testosterone maintained intratesticular testosterone concentration close to normal, despite full suppression of the pituitary's own LH. That's the explanation for "why this works," while the Hsieh et al. study provides an approximate answer to "how far this gets you in clinical practice."

Beyond spermatogenesis itself, hCG also has a noticeable effect on something that matters just as much subjectively to many men: testicle size. Testicular atrophy is one of the most visible, physical effects of TRT suppressing LH without additional intervention — the testes, deprived of their own hormonal work, shrink over time. hCG, by stimulating Leydig cells the way natural LH would, helps maintain their metabolic activity and, with it, their volume. This is an effect many patients notice and value regardless of whether they're actively planning a child — for some men it's a separate, standalone reason to consider hCG.

This is practically the most important distinction in this whole topic, and also the one most often overlooked in conversations about hCG: the goal of "preserving fertility for the future, just in case" and the goal of "actively trying for a child right now" are two completely different clinical situations that call for a different approach.

In other words: the more "active" and "urgent" the plan to have a child, the less room there is for a wait-and-see approach with hCG alone, and the more warranted it is to involve a male-infertility specialist right from the start, rather than only after months of trying haven't produced a result.

In the large majority of cases, hCG is a separate line item on the prescription and a separate cost, added on top of the base testosterone therapy, not an integral, "included" part of it. In Poland, this usually means an additional visit or consultation, during which the doctor assesses whether adding hCG is warranted, plus an additional prescription and the cost of the preparation itself and the supplies needed to prepare the injections (syringes, diluent, needles). On top of that comes the need for more frequent, additional monitoring — including estradiol, since hCG, by raising local testosterone production, indirectly also increases the pool of substrate for aromatization into estrogen, and in rarer cases it's also worth checking liver function markers with long-term use.

This isn't a prohibitive cost for most patients already on TRT under a doctor's care, but it's worth factoring into the therapy budget upfront, rather than treating it as a surprise that shows up with the first prescription.

How you feel, your libido, or even the subjective impression that your testicles "haven't shrunk" aren't sufficient proof that hCG is doing what it was added to do. The only reliable way to assess its effectiveness for fertility is a regular semen analysis — a spermiogram — performed at a diagnostic lab, ideally repeated a few months after starting or changing the hCG dose, since the human spermatogenesis cycle takes about 2–3 months and an earlier measurement won't yet reflect the therapy's full effect.

hCG added to TRT is one of the best-described, practical strategies for limiting testosterone therapy's impact on fertility and testicular volume — but it's a risk-management strategy, not a guarantee. Data from the Hsieh et al. (2013) study are encouraging, but come from a small, retrospective group, and dosing in clinical practice still varies between centers for lack of a single, standardized protocol. If preserving fertility is a real priority for you, not just a theoretical future option, treat hCG as part of a broader conversation with your doctor — one that includes a baseline spermiogram, regular follow-ups, and an honest assessment of whether, in your situation, especially if you're actively planning a child right now, an entirely different strategy than TRT might be the better choice.